Gilead Sciences’ Kite Pharma will sell its stake in China’s Fosun Kite Biotechnology nearly eight years after forming the ...

It was a busy week for the biotech sector with a lot of important data readouts at the European Society for Medical Oncology ...

The threat of a lack of millions of pounds worth of funding has added to Cornwall Council's financial problems ...

Raymond James has recently raised Gilead Sciences, Inc. (GILD) stock to Outperform rating, as announced on July 8, 2024, according to Finviz. Earlier, on May 1, 2024, Maxim Group had reiterated the ...

Two years ago, a few friends who regularly met at the Speckled Paw in Mt. Gilead formed a group called the Dollar Club. This ...

Twice-yearly lenacapavir was found to be superior to daily emtricitabine 200mg and tenofovir disoproxil fumarate 300mg.

A Freemasons Lodge has made a “lasting impact” after donating £1,000 to the 1st Leverington Rainbows group. The donation from ...

The latest trading day saw Gilead Sciences (GILD) settling at $83.08, representing a -0.1% change from its previous close.

In Type 1 diabetes (T1D), insulin-producing β-cells are killed by islet-infiltrating immune cells in a process called “insulitis”. T1D results in a critical requirement for exogenous insulin and ...

A new study reveals that two yearly injections of the drug lenacapavir is more effective at preventing HIV than a daily pill ...

The published belrestotug/dostarlimab data is still too immature to prove the combination’s capability to disrupt the NSCLC ...

Buy GILD slightly over 77.18 target n/a stop loss @ 76.96. Details The technical summary data tells us to buy GILD near 77.18, but there is no current upside target from the summary table. In this ...